The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy.
Dec 19, 2017
0
3
Intensive surveillance including a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) exam every six months was far more effective in detecting breast cancer in younger women with a high-risk genetic profile than ...
Dec 8, 2017
0
80
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...
Dec 8, 2017
0
3
In a new paper published in Nature Communications, a team led by Saint Louis University researcher Alessandro Vindigni, Ph.D. shares new information about how BRCA-deficient cancer cells operate, interact with chemotherapy ...
Nov 28, 2017
0
19
A study that looked at mainstreaming genetic counselling for ovarian cancer to support screening programmes in Malaysia was presented at the ESMO Asia 2017 Congress. The preliminary results of the MaGiC study show that most ...
Nov 20, 2017
0
1
The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had ...
Nov 1, 2017
0
5
(HealthDay)—Qualitative computed tomography (CT) features differ between patients with BRCA-mutant high-grade serous ovarian cancer (HGSOC) and patients with BRCA wild-type HGSOC, according to a study published in the November ...
Oct 31, 2017
0
1
A University of Arizona Cancer Center research team is engaged in a series of studies to investigate how genistein, a component of soy foods, might suppress the development of breast cancer.
Oct 30, 2017
0
31
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...
Oct 20, 2017
0
4
New research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy (CT) treatment based on their specific BRCA1 expression levels, as opposed to providing ...
Oct 17, 2017
0
0
